



ASX & MEDIA RELEASE

10 JANUARY 2018

## MEDLAB GRANTED LICENCES TO SELL OR SUPPLY CANNABIS (CBD &/OR THC) IN AUSTRALIA

Medlab Clinical Limited (ASX: MDC) is pleased to announce that the Company has received the following licence from the Victorian State Government:

- Licence to Sell or Supply Schedule 8\* or Schedule 9\* Drugs (limited to cannabis and its derivatives) – NanaBis™ (cannabis CBD:THC product) and NanaBidual™ (cannabis CBD product) will be sold under this licence.

As NanaBis™ is manufactured and distributed from Victoria, a licence was required to be provided from the Victorian Government. This licence allows Medlab to sell in other states.

As previously announced, Medlab's Australian manufactured cannabis based medicine, (NanaBis™) is expected to be available in late February 2018. These licences are the next step in the commercialisation process of NanaBis™.

NanaBis™ is currently in production at Pharmaceuticals Packaging Professionals in Melbourne. Medlab will be selling under the TGA's Special Access Scheme to patients with specific needs, late February this year.

According to Medlab CEO, Sean Hall, continued support from the medical community, the various states and Federal Government for cannabis-based medicine was pleasing.

"We are seeking to make our medicines distinctive, giving medical practitioners, Government and industry stakeholders such as the Australian Medical Association (AMA) confidence in prescribing our products. This Licence to Sell, combined with the recently renewed import licence (allowing for significant increases in the amounts of cannabis allowed to be imported) gives Medlab a significant advantage in being able to assist the medical community in treating advanced cancer pain," Sean Hall said.

\*For explanation of the relevant TGA Scheduling, refer to the attached Appendix.

See attached for Key Milestones Achieved with reference to Medlab's cannabis project.

---

**ISSUED FOR:** MEDLAB CLINICAL LTD (ASX: MDC) – [www.medlab.co](http://www.medlab.co)

**FOR FURTHER INFORMATION:** SEAN HALL, CEO, MEDLAB CLINICAL  
TEL: +61 2 8203 9520, [sean\\_hall@medlab.co](mailto:sean_hall@medlab.co)

ISSUED BY: HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL  
TEL +61 2 9286 1226 OR +61 468 960 457, [marcha.vandenheuvel@hkstrategies.com](mailto:marcha.vandenheuvel@hkstrategies.com)

**ABOUT MEDLAB – [www.medlab.co](http://www.medlab.co)**

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, Nanocelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.

## APPENDIX 1 - SCHEDULING BASICS

Scheduling is a national classification system that controls how medicines and poisons are made available to the public. Medicines and poisons are classified into Schedules according to the level of regulatory control over the availability of the medicine or poison, required to protect public health and safety.

The Schedules are:

<b>Schedule 1</b>	Not currently in use
<b>Schedule 2</b>	Pharmacy Medicine
<b>Schedule 3</b>	Pharmacist Only Medicine
<b>Schedule 4</b>	Prescription Only Medicine OR Prescription Animal Remedy
<b>Schedule 5</b>	Caution
<b>Schedule 6</b>	Poison
<b>Schedule 7</b>	Dangerous Poison
<b>Schedule 8</b>	Controlled Drug
<b>Schedule 9</b>	Prohibited Substance
<b>Schedule 10</b>	Substances of such danger to health as to warrant prohibition of sale, supply and use

Reference: Therapeutic Goods Association - <https://www.tga.gov.au/scheduling-basics>

## APPENDIX 2 – KEY MILESTONES ACHIEVED

- July 2015, Medlab is granted a medical cannabis research licence
- November 2016, Medlab was granted a licence to import cannabis from the Therapeutics Goods Association (TGA).
- June 2017 Medlab received Human Research Ethics Committee approval to conduct a human trial at Royal North Shore Hospital with advanced stage cancer patients suffering intractable pain. The trial will be the first of its kind in the pain/oncology area and is expected to commence shortly.
- August 2017, Medlab received an import permit for the first shipment of cannabis oil from Canada.
- October 2017, Medlab and Aphria (TSX:APH) jointly announced completion of our first medical cannabis (CBD/THC) shipment to Australia
- November 2017, the annual TGA licence to import cannabis was renewed with substantially increased quantities of CBD and THC cannabis.
- December 2017, Medlab and Aphria complete the second medical cannabis shipment into Australia
- January 2018, granted licence to sell cannabis

Medlab CEO, Sean Hall said, “the above summary illustrates how much Medlab has achieved in such a short period of time, especially given the complexities of the cannabis industry”.